Oct. 22 at 5:37 AM
$STIM Entering here. Very optimistically.
If Sullivan can pull off the integration of Greenbrook and synergize manufacturing into clinic operations, the sky is the limit.
Being that Neurostar is the not only empirically best TMS system, it's the only one approved for adolescents by the FDA, creating a giant moat in itself. Spravato being embraced by FDA adds a ton of potential to their valuation, which I don't believe is priced in as Greenbrook expands.
The numbers are so juicy even with a rocky road we're still undervalued. There's serious potential here.
